PALI (Palisade Bio) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio 3-Year Revenue Growth Rate?

Palisade Bio's Revenue per Share for the three months ended in Jun. 2024 was $0.00.

During the past 12 months, Palisade Bio's average Revenue per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Palisade Bio's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Palisade Bio's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palisade Bio's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Palisade Bio's 3-Year Revenue Growth Rate falls into.

Palisade Bio 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Palisade Bio (NAS:PALI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Palisade Bio 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Palisade Bio's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisade Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008

Website

https://www.palisadebio.com

Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Executives

Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley	officer: Chief Financial Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones	officer: Chief Medical Officer	70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae	officer: Chief Operating Officer	675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam	director, officer: Chief Executive Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson	officer: Chief Medical Officer	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center	10 percent owner	2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz	director	C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei	director	P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter	director, officer: Executive Chairman	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma	director	14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142